Glioblastoma in elderly patients: solid conclusions built on shifting sand?
- 18 July 2017
- journal article
- review article
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 20 (2) , 174-183
Abstract
Management of glioblastoma in the elderly population is challenging. In the near future, more than half of patients with this tumor will be over the age of 65. Clinicians have been historically reluctant to treat such patients with the same intensity as younger patients. Due to upper age limits or poor accrual of elderly patients in clinical trials, randomized data for this patient population have been relatively sparse until recently. In this review, we will discuss the concept of an elderly patient population, describe evidence for molecular differences in glioblastoma of elderly versus young patients, evaluate recent first-line trials studying glioblastoma in elderly patients, and discuss best therapeutic practices including the value of molecular testing.Keywords
This publication has 60 references indexed in Scilit:
- Improving neuro-oncological patients care: basic and practical concepts for nurse specialist in neuro-rehabilitationJournal of Experimental & Clinical Cancer Research, 2012
- Does age matter? - A MRI study on peritumoral edema in newly diagnosed primary glioblastomaBMC Cancer, 2011
- Identification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of GliomaCancer Cell, 2010
- Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1Cancer Cell, 2010
- MGMT METHYLATION IS A PROGNOSTIC BIOMARKER IN ELDERLY PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMANeurology, 2009
- Aging and Environmental Exposures Alter Tissue-Specific DNA Methylation Dependent upon CpG Island ContextPLOS Genetics, 2009
- Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trialThe Lancet Oncology, 2009
- Bevacizumab and chemotherapy for recurrent glioblastomaNeurology, 2009
- Gene expression analysis of glioblastomas identifies the major molecular basis for the prognostic benefit of younger ageBMC Medical Genomics, 2008
- A new method of classifying prognostic comorbidity in longitudinal studies: Development and validationJournal of Chronic Diseases, 1987